Asian Journal of Cardiology Research

Background: The noncommunicable disease has taken place on communicable disease in recent years. Acute myocardial infarction most common cause of cardiovascular death. In this subcontinent it occurs at an early age and more aggressively. Thrombolytics therapy remains cornerstone of treatment despite advancement of coronary revascularization. Streptokinase is widely use due to high cost of tPA (tissue plasminogen activators). Urokinase is similar drugs as streptokinase but has additional benefit like it is not immunogenic so can be used in recurrent MI, rate of thrombolysis is faster than streptokinase, and exerts some degree of fibrin specificity.

Aim: We assess the role of urokinase as a thrombolytic in our acute ST elevation myocardial infarction patient.

Design and Methods: This is an observational study. The respondent number was fifty as per selection criteria. All data analyzed by using computer-based SPSS (statistical programmed for social science) programmed.

Results: Out of fifty patients male were 42(84%) and female were 8(16%). Highest number of patients 16(32%) between age group 45-54 years in male and in female 6 (12%) was in age group 55-64 years. Thirty (60%) patients suffered from anterior myocardial infarction and twenty (40%) patients suffered from inferior myocardial infarction. Thirty-six (72%) patients experienced complete relief of chest pain and  resolution of ST segment after urokinase therapy. Regarding outcome forty-two (84%) patients successful recovered and eight (16%) patients had died.

Conclusion: The study has shown that male was affected by myocardial infarction more than the female and in earlier age. Although good number of patients recovered after thrombolysis with urokinase, still a few patients succumbed to death.